United Therapeutics Q1 revenue falls 2% to $781.5M, launches $2B buyback program

Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

• high

  Q1 2026 revenues declined 2% YoY to $781.5M while net income fell 15% to $274.9M ($5.82 per diluted share vs. $6.63 prior year), driven by 22% drop in Nebulized Tyvaso sales partially offset by 9% Tyvaso DPI growth.

  Exhibit 99.1 verify on EDGAR →
• high

  Cost of sales surged 44% to $133.4M, including a $26.8M estimated loss from a Tyvaso DPI commercial supply agreement to maintain sufficient inventory for patient needs.

  Exhibit 99.1 verify on EDGAR →
• high

  Board approved $2B share repurchase program through March 2027; company executed $1.5B via accelerated repurchase agreements with Citibank in Q1, receiving 2.16M shares, with $500M authorization remaining.

  Exhibit 99.1 verify on EDGAR →